The oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) is funded for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria (updated 1 October 2023) and to comprehensive drug interaction guidance.
8 minutes to Read + 7 minutes to Delve
31 March 2022